Lysyl Oxidase, Semaphorin 7a and Semaphorin 3a in Patients With Systemic Sclerosis

Hillel Yaffe Medical Center

Status: Unknown

Conditions: Systemic Sclerosis

Treatments: Other: Blood test

Study type: Interventional

Funder types: Other

Identifiers

NCT01943968

HYMC-075-13

Details and patient eligibility

About

The aim of our study is to find a biomarker for fibrosis or vasculopathy in systemic sclerosis. We will evaluate a possible correlation between semaphorin 7a, semaphorin 3a and lysyl oxidase and fibrosis (lung and skin) or vasculopathy in patients with systemic sclerosis. The results obtained may help us diagnose these complications of systemic sclerosis and hopefully even monitor patient treatment.

Enrollment: 30 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Systemic Sclerosis Patients
• Written consent to participation in study

Exclusion criteria

• Serious active medical condition
• Other autoimmune rheumatic disease
• Current or past allergic/inflammatory reaction
• Liver disease
• Pregnant or breastfeeding
• Illegal drug or alcohol abuse

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

Systemic sclerosis patients

Other group

Description:

Systemic sclerosis patients will have blood tested for fibrotic enzyme levels

Treatment:

Other: Blood test